News | Patient Positioning Radiation Therapy | October 25, 2018

Brainlab Introduces ExacTrac Dynamic at ASTRO 2018

Radiotherapy patient positioning and monitoring technology now consolidates multiple spatial tracking technologies

Brainlab Introduces ExacTrac Dynamic at ASTRO 2018
Radiotherapy patient positioning and monitoring technology now consolidates multiple spatial tracking technologies

October 25, 2018 — Brainlab unveiled ExacTrac Dynamic at the American Society for Radiation Oncology (ASTRO) meeting, Oct. 21-24 in San Antonio, Texas. This concept for radiotherapy patient positioning and monitoring offers value on multiple fronts, including expanded clinical indications, broad technological advancements, enhanced user and patient experience, and technology consolidation. ExacTrac Dynamic is the next generation of ExacTrac X-Ray, Brainlab’s positioning and monitoring solution for radiotherapy treatments.

ExacTrac Dynamic addresses a full range of patient positioning and monitoring requirements that heretofore have been achieved, in most cases, by employing multiple systems combined with different internal tracking and surface scanning technologies. ExacTrac Dynamic is seamlessly integrated with a wide range of high-end linear accelerators and designed to deliver high-precision tracking and verification, while addressing the challenges associated with treating moving targets. All of these are critical requirements for delivering extremely effective and high doses in precision radiotherapy.

“We had the opportunity to be the first institution to enter into a strategic partnership for the development of ExacTrac Dynamic, as we were looking for a technology that could become the new standard for patient positioning and monitoring in Copenhagen,” commented Lars Dahl Allerup, new business development manager, corporate procurement, Capital Region of Denmark. “As a long standing partner of Brainlab, we have always been convinced of the superior performance of ExacTrac X-Ray for cranial treatments. What is important for us moving forward is to source technology like ExacTrac Dynamic that allows us to continue treating cranial indications but also take care of the larger patient population at the Herlev Hospital and Rigshospitalet, with a platform redesigned to monitor all external beam treatment indications.”

New high-speed surface tracking incorporates 300,000 3-D surface points to externally monitor patient position and detect movement during treatment. Each of the surface points acquired by the ExacTrac Dynamic structured light system are matched to a heat signal generated by a thermal camera, creating another dimension in which to track the patient’s position consistently and with great accuracy. The advanced surface tracking with ExacTrac Dynamic is not impacted by room lighting, reflections or skin tone, and has very low latency.

Internal motion caused by normal respiration must be addressed to ensure safe and effective treatments. In addition to external tracking, integrated X-ray monitoring with ExacTrac Dynamic verifies the patient’s position internally with real-time imaging, at any treatment position. The system offers ways to monitor clinical indications that are complicated by internal motion with additional workflows, such as deep inspiration breath hold and internal anatomy verification, providing confidence in true dose sparing of critical anatomy.

Customers will still take advantage of ExacTrac X-ray’s historical benefits, including high performance, non-coplanar capabilities and submillimetric precision. Cranial positioning and monitoring offers streamlined immobilization, non-coplanar imaging, Mu-triggered monitoring and gantry-angle triggered monitoring.

ExacTrac Dynamic simplifies frameless fixation with three moldable thermoplastic mask options designed with patient comfort in mind. Deep integration with linear accelerators from both Elekta and Varian Medical Systems allow positioning and monitoring workflows to function seamlessly, including automatic patient loading, gantry triggered imaging and automated beam-hold.

For more information: www.brainlab.com

Related Content

Global radiotherapy market revenue is set to expand from $7,222.4 million in 2019 to $17,194.4 million by 2030, at an 8.4% CAGR between 2020 and 2030, the key factor driving the market growth is the increasing number of cancer cases, according to the report published by P&S Intelligence.

Image courtesy of Elekta

News | Radiation Therapy | August 06, 2020
August 6, 2020 — Global ...
Siemens AG is continuing to rigorously execute its Vision 2020+ strategy and therefore expressly welcomes Siemens Healthineers AG’s acquisition of a 100 percent stake in Varian Medical Systems, Inc., a U.S. company active in the area of cancer research and therapy.

Getty Images

News | Radiology Business | August 03, 2020
August 3, 2020 — Siemens AG is continuing to rigorously execute its Vision 2020+ strategy and therefore expressly wel
JAMA Oncol. Published online  July 30, 2020. doi:10.1001/jamaoncol.2020.2783

Table 1. JAMA Oncol. Published online  July 30, 2020. doi:10.1001/jamaoncol.2020.2783

News | Coronavirus (COVID-19) | July 31, 2020
July 31, 2020 — An article published in JAMA...
It has been estimated that the overwhelming focus on COVID-19 could cause up to 35,000 excess cancer deaths in the UK during the next 12 months, and  Zegami, the Oxford University data visualization spin-out which has worked on several projects focused on the detection, diagnosis, or management of cancer, is calling for greater use of technology to speed up the process of diagnosis and treatment.

Getty Images

News | Radiation Oncology | July 29, 2020
July 29, 2020 — It has been estimated that the overwhelming focus on...
In I-131 cancer therapy, decay events damage sensitive DNA within a tumor cell nucleus, causing catastrophic single and double strand breaks. Clinical use of antibody-delivered Auger emitters could open a window for the targeted destruction of extracellular COVID-19 virions, decreasing the viral load during active infection and potentially easing the disease burden for a patient. View all figures from this study.  http://jnm.snmjournals.org/content/early/2020/07/16/jnumed.120.249748.full.pdf+html

In I-131 cancer therapy, decay events damage sensitive DNA within a tumor cell nucleus, causing catastrophic single and double strand breaks. Clinical use of antibody-delivered Auger emitters could open a window for the targeted destruction of extracellular COVID-19 virions, decreasing the viral load during active infection and potentially easing the disease burden for a patient. View all figures from this study.

 

News | Coronavirus (COVID-19) | July 22, 2020 | Dave Fornell, Editor
July 22, 2020 — One of the first studies has been published that looks at the use of...
World's largest radiation oncology meeting will offer full conference on interactive platform October 25-28, 2020
News | ASTRO | July 09, 2020
July 9, 2020 — Registration opens today for the American Society for Radiation Oncology's (...
Radiotherapy has been used to treat cancers for more than a century and continues to be utilized in cancer treatment plans today. Since the introduction of radiotherapy, clinicians have been working tirelessly to further refine treatments to better target cancer.
Feature | Radiation Therapy | July 06, 2020 | By Yves Archambault
Everything has room for improvement, right? Right. When it comes to cancer care, it is no different.
Proton therapy has evolved, and future predictions include smaller systems, more sophisticated proton dosimetry and devices that manipulate the proton beam
Feature | Proton Therapy | July 06, 2020 | By Minesh Mehta, M.D.
The field of proton...